Patients with lower levels of vitamin D had more subclinical lesions.
Low vitamin D levels are a risk factor for the development of multiple sclerosis (MS). Intervention trials are under way to determine whether vitamin D supplementation can reduce the severity for those with established MS. Now, researchers report results of an analysis from the BEYOND study, a large clinical trial comparing standard-dose interferon β-1b to double-dose interferon β-1b or glatiramer acetate. Vitamin D samples were collected from 1796 trial participants at baseline, 6 months, and 12 months. Magnetic resonance imaging (MRI) was done at baseline and annually.
MRI T2 lesion volume and gadolinium-enhancing lesion numbers were each inversely correlated with baseline and 12-month, season-adjusted 25-hydroxyvitamin D levels (25[OH]D).…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)